Financial Data and Key Metrics Changes - Net revenue for Q1 2025 was $162 million, an increase of 10% year-over-year, marking the twentieth consecutive quarter of growth since the IPO in 2020 [6][18] - Gross profit rose to $62.5 million, representing 38.5% of net revenue, down from 39.8% the previous year due to increased investments and less efficient operations [19][20] - Net income decreased by 11.2% to $16.9 million, or $0.37 per diluted share, compared to $19 million, or $0.43 per diluted share in Q1 2024 [21] - Adjusted EBITDA for Q1 2025 was $27.5 million, or 16.9% of net revenue, down from 19.7% in the prior year [21] Business Line Data and Key Metrics Changes - The Butter business saw robust growth with net revenue up 41% year-over-year [7] - Egg product demand remains strong, but supply constraints have limited volume growth [8][16] - The company added approximately 25 new family farms in Q1 2025, increasing its network to over 450 farms [13] Market Data and Key Metrics Changes - Brand awareness reached 31% by the end of Q1 2025, a five-point increase since the beginning of the year [9] - The company is currently in 11.3% of U.S. households, indicating significant room for growth [11] Company Strategy and Development Direction - The company aims to achieve $1 billion in net revenue by 2027, with a gross margin target of about 35% and an adjusted EBITDA margin of 12% to 14% [14][28] - Investments in supply chain infrastructure and farm expansion initiatives are expected to support sustained growth [14][29] - The company plans to implement a modest price increase for shell egg products to offset anticipated cost impacts from tariffs [15][26] Management's Comments on Operating Environment and Future Outlook - Management expects volume growth headwinds to ease in Q2 2025, leading to reaccelerated net revenue growth [16] - The company remains confident in its ability to navigate macroeconomic uncertainties and consumer behavior changes due to its strong brand loyalty [84] - Management reiterated its full-year guidance for net revenue of at least $740 million, representing at least 22% growth compared to 2024 [24][25] Other Important Information - The company is on track with its digital transformation initiative, with the launch of a new ERP system updated to early fall 2025 [27] - The company is addressing a material weakness in internal controls related to revenue recognition, with no revenue inconsistencies found [23] Q&A Session Summary Question: Impact of price increase on retailer pricing - Management indicated that pricing is primarily aimed at protecting gross margins and maintaining strong relationships with retail partners [39] Question: Current egg supply and retailer orders - Management noted that while the category is improving, supply constraints still exist, and elevated orders from retailers reflect ongoing demand [41] Question: Volume growth expectations for the year - Management expects volume growth to accelerate as new farms come online, with Q2 serving as a transition point [48] Question: Impact of tariffs on pricing and costs - Management confirmed that while tariffs could impact costs, the price increase is expected to cover these impacts [62] Question: Retail distribution increase clarification - The increase in reported distribution from 24,000 to 26,000 stores was due to a change in data providers rather than a significant increase in new retailers [67] Question: Consumer behavior amidst macro uncertainty - Management observed that brand loyalty remains strong, with consumers less likely to trade down even in challenging economic conditions [84]

Financial Data and Key Metrics Changes - Total reported revenue for Q1 2025 was $693 million, down from $711 million in the prior year, primarily due to lower COVID and donor screening revenue [18] - Excluding COVID and donor screening, the company achieved a mid single-digit revenue growth of 6% [18] - Adjusted EBITDA margin improved by 450 basis points year over year to 23%, with adjusted diluted EPS increasing by 68% to $0.74 [24][25] Business Line Data and Key Metrics Changes - Labs business, accounting for 54% of total revenue, grew by 7%, driven by clinical chemistry and immunoassay testing [10] - Immunohematology business grew by 4%, maintaining its global leadership position [10] - Point of Care business represented 25% of Q1 revenue and grew by 8% excluding COVID, with strong flu sales leading to an 18% year-over-year growth [10] - Molecular Diagnostics business grew by 11% excluding COVID, with ongoing clinical trials for the Savanna respiratory panel [11] Market Data and Key Metrics Changes - Revenue from the "Other" region (Japan, Asia Pacific, Latin America) grew by 12%, driven by a 17% increase in Labs revenue [19] - North America revenue declined by 6% due to lower COVID revenue and donor screening wind down, but grew by 5% when excluding these factors [19] - Europe, Middle East, and Africa grew by 9%, while China revenue remained flat, primarily due to order timing and decreased Triage revenue [20] Company Strategy and Development Direction - The company is focused on a narrow set of strategic initiatives, including increasing platform content and utility, expanding margins, and enhancing commercial execution [11] - Plans to realize $100 million in annualized cost savings, with $50 million expected in the first half of 2025 [12] - The company aims to maintain its manufacturing footprint and continue investing in U.S.-based manufacturing and R&D [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and operational discipline, highlighting strong Q1 results and ongoing initiatives [9] - The company anticipates potential tariff impacts of $30 million to $40 million in 2025 but believes mitigation plans will offset these impacts [15] - Full-year 2025 financial guidance remains unchanged, with expectations for total reported revenue between $2.6 billion and $2.81 billion [27] Other Important Information - The company has invested nearly $1 billion in U.S.-based manufacturing and R&D over the past three years [13] - Adjusted free cash flow for Q1 2025 was $47 million, representing 29% of adjusted EBITDA [26] - The company plans to refinance its debt in the second half of 2025 or early 2026, depending on market conditions [31] Q&A Session Summary Question: Can you elaborate on the tariff impact and pricing actions? - Management indicated that selective pricing actions are being considered to offset tariff impacts, but competitive market conditions must be taken into account [36][37] Question: Will tariff impacts affect long-term manufacturing plans? - Management does not expect changes to the overall manufacturing footprint, emphasizing the importance of their global manufacturing network [38] Question: How confident is the company in mitigating tariff impacts? - Management expressed confidence in fully mitigating tariff impacts through various actions, including cost reductions and realigning inventories [43] Question: What underpins the confidence in China's growth rate? - Confidence in mid to high single-digit growth in China is based on strong performance in labs and immunohematology, despite some softness in Triage sales [49] Question: What is the status of the Savanna program? - The company is focused on completing the RBP4x submission to the FDA and is not speculating on outcomes beyond that [45][61] Question: How is the respiratory sales performance impacting guidance? - Management expects to maintain the guidance range for COVID revenue despite a decline, as flu sales have been strong [56][58]

Financial Data and Key Metrics Changes - The company generated $244.7 million of adjusted EBITDA in Q1 2025, down slightly compared to the same quarter last year despite a 20.5% decline in revenue [9][10] - Total adjusted SG&A expenses were $57.5 million, representing 85.6% of gross profit, down from $72.6 million or 87.9% of gross profit in the same quarter last year [10] - Cash outflows from operating activities were $6.9 million for Q1 2025, compared to cash inflows of $17 million for the same period in 2024 [14] Business Line Data and Key Metrics Changes - The Powersports Group sold 13,186 total major units, down 20.5% year over year, with new unit sales down 23.7% and pre-owned unit sales down 13.9% [11] - Gross margins for new units improved to 13.5% from 12.5% year over year, while pre-owned gross margins were 16.3%, down from 19.5% due to an elevated margin in the previous year [11] - Revenue from the powersports dealership group was $239.2 million, down 18.5% year over year, primarily due to lower major unit volume [13] Market Data and Key Metrics Changes - The asset-light vehicle transportation services segment, Wholesale Express, saw revenue decline by 61.5% year over year, with gross profit decreasing 68.6% to $1.1 million [14] - The overall decline in unit sales during the quarter impacted revenue and gross profit across various segments [12] Company Strategy and Development Direction - The company is focused on improving operational discipline and customer service, aiming for long-term financial success despite current challenges [8] - New key management additions are expected to strengthen the company's market position and align with strategic growth goals [6][7] - The company is actively evaluating opportunities to optimize its capital structure and lower its cost of capital [15] Management's Comments on Operating Environment and Future Outlook - The operating environment remains challenging due to tariffs and shifting consumer preferences, but the company is seeing robust demand in the pre-owned segment [7][8] - Management expressed confidence in the actions taken to position the company for long-term success, despite a difficult macroeconomic backdrop [4][8] Other Important Information - The company is engaged in a comprehensive search for a new CFO to lead future growth [6] - The company has fully repaid $38.8 million of convertible notes due on January 2 [14] Q&A Session Summary Question: How aggressive does the company want to be with the cash offer tool for pre-owned inventory? - The company can be aggressive with the cash offer tool, but it depends on the quality of the inventory available [17][18] Question: What are the expectations for inventory levels by year-end? - The company expects inventory levels to be about where they ended in 2024, possibly a little higher due to inflation [20][22] Question: What is the message from OEM partners regarding tariffs? - OEMs are currently absorbing tariff costs, and there is hope for a return to normal operating conditions soon [25][26]

Financial Data and Key Metrics Changes - The company achieved sales of approximately $168 million for the first quarter, with organic sales up 2.8% compared to the previous year [8][9] - Adjusted diluted earnings per share were $0.26, and adjusted EBITDA was approximately $22 million, with adjusted gross margins at 56.7% [9] - The balance sheet remains strong with $97 million in cash and $107 million in debt as of March 31 [9] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems segment grew almost 9% organically compared to the prior year, reaffirming its leading position in long-term, short-term, and neonatal internal feeding [13] - The Pain Management and Recovery segment saw normalized organic sales up 2.4%, with the radiofrequency ablation business posting near double-digit growth [15][16] - The hyaluronic acid injections and intravenous infusion product lines reported a decline of over 30% due to pricing pressures [18] Market Data and Key Metrics Changes - The company anticipates a softer Q2 for the Specialty Nutrition Systems segment due to distributor order timing but remains confident in its strength for the rest of the year [19] - The impact of tariffs is expected to be significant, with an estimated $15 million in incremental tariff-related manufacturing costs for the year [20][22] Company Strategy and Development Direction - The company is focused on transformation efforts around portfolio, organization structure, and cost management to enhance growth [6][10] - Strategic M&A opportunities are being pursued to align with return criteria, with two smaller transactions already closed this year [10] - The organizational focus has been refined to improve operating processes and capitalize on growth opportunities [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start to the year, particularly in strategic segments, despite a dynamic economic environment [23] - The revised adjusted EPS estimate reflects a reasonable view of the tariff impact on full-year results [23] - The company is actively monitoring the tariff situation and executing initiatives to reduce risks [23] Other Important Information - The company has transitioned to reporting under two operating segments: Specialty Nutrition Systems and Pain Management and Recovery [11] - A disciplined cost management culture has been embedded to help offset tariff pressures [19] Q&A Session Summary Question: Thoughts on second quarter performance relative to the first - Management indicated that while Q2 may see a slight decline due to distributor order dynamics, they maintain confidence in full-year guidance [28][30] Question: Insights on leadership experience and strategic focus - The new CEO emphasized a focus on optimizing commercial strategies and partnerships to enhance market position [35][36] Question: Clarification on tariff assumptions and impacts - Management provided details on expected tariff-related costs and mitigation strategies, including leveraging international agreements [41][44]

Summary of Key Points from the Conference Call on China Healthcare Equities Industry Overview - The conference focused on the **China Healthcare sector**, particularly the impact of US tariffs on the pharmaceutical supply chain and related industries [2][21]. Core Insights - **Tariff Impact Ranking**: The impact of tariffs is expected to be highest on medical consumables, followed by devices and drugs [2]. - **Timeline for Tariffs**: Tariffs on US pharmaceutical imports may commence within one to two months due to ongoing investigations [2]. - **Impact on Exporters**: Small and medium-sized exporters of low-end medical consumables are anticipated to be most affected, with major CDMOs like Wuxi AppTec, Pharmaron, and Genscript facing 30-50% revenue exposure to the US [2][21]. - **Risk Management**: Large companies are managing risks through planned production capacity shifts to ASEAN/Europe and maintaining high inventory levels (two to three years) [2]. - **API Exporters**: The risk for API exporters is considered manageable in the short term due to China's established supply chain role, despite having double-digit US revenue exposure [2]. Financial Projections - **Revenue and Profit Margin Erosion**: Scenario analysis indicates potential revenue and net profit margin erosion of approximately 5% and 1 percentage point across sub-sectors due to tariffs [3]. - **CDMO Impact**: CDMOs could see up to a 6% revenue impact and a 5-10% decrease in net profit margins [3]. - **Cost Inflation**: Import-dependent segments, such as IVD reagents, may experience around 1% cost inflation, slightly squeezing margins [3]. Market Dynamics - **Global Supply Chain Shifts**: The global supply chain is shifting, but short-term offsets are expected due to stockpiling [2]. - **Domestic Substitution**: There is an expectation of accelerating domestic substitution in the MedTech sector due to import weaknesses caused by tariffs [9]. - **Market Concentration**: A higher level of market concentration is anticipated in the MedTech subsector [9]. Company-Specific Insights - **Limited US Exposure**: Chinese innovative drugs are forecasted to have almost no sales exposure to the US, with limited impact from R&D cost increases due to higher export prices [7]. - **CDMO Resilience**: CDMOs are expected to manage tariff impacts effectively, with 80% of tariff expenses potentially passed through to US clients [8]. - **MedTech Companies**: Companies like Mindray and United Imaging are expected to face low single-digit cost impacts due to their low US exposure [9]. Export Data - **China Healthcare Exports**: Total exports from the China Healthcare sector reached **USD 107.99 billion** in 2024, marking a **5.8% year-on-year increase** [15]. - **Export Composition**: APIs accounted for approximately **40%** of total exports, while IVDs made up **21%** [15][18]. Conclusion - The China Healthcare sector is navigating potential tariff impacts with strategic adjustments and risk management practices. While certain sub-sectors may face challenges, the overall resilience of the industry, particularly in API production and innovative drug development, is expected to mitigate significant adverse effects.

Financial Data and Key Metrics Changes - JBT Morell's first quarter revenue exceeded guidance by $19 million, driven by better-than-expected equipment shipments and strong recurring revenue [17] - Adjusted EBITDA margin was 13.1%, outperforming guidance by 60 basis points, attributed to volume flow-through, favorable mix, and good expense control [17] - Free cash flow for the quarter was $18 million, including approximately $42 million in one-time M&A related payments [19] Business Line Data and Key Metrics Changes - JBT segment revenue increased by 4% year over year, or 5.6% on a constant currency basis, with adjusted EBITDA of $61 million, a 6% increase [18] - MRL segment revenue was flat year over year but grew by 2% on a constant currency basis, with adjusted EBITDA increasing by 19% to $51 million [19] Market Data and Key Metrics Changes - Demand from the poultry industry continued to recover, contributing to a 12% year-over-year increase in orders [6] - The company experienced broad-based strength across global regions, with healthy orders in meat, beverage, pharma, and pet food [6] Company Strategy and Development Direction - The company is focused on integrating its operations to enhance service capabilities and product offerings, positioning itself as a leader in sustainable food solutions [15] - JBT Morell is taking actions to mitigate tariff impacts, including securing concessions from suppliers and implementing selective pricing actions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage near-term impacts from tariffs and macroeconomic uncertainty, highlighting the resilience of recurring revenue [11][23] - The company has temporarily suspended full-year financial guidance due to uncertainty but provided second-quarter guidance, expecting revenue of $885 million to $915 million [22] Other Important Information - The estimated annualized cost impact from tariffs is approximately $50 million to $60 million, with efforts underway to mitigate these costs [10] - The company is on track to achieve targeted cost synergies of $150 million by the end of 2027 [20] Q&A Session Summary Question: Update on guidance and customer behavior - Management indicated that the decision to pull full-year guidance was due to lack of clarity in the environment, with no significant changes in customer behavior noted [26][28] Question: Backlog and order delays - Management clarified that the backlog was affected by foreign exchange and adjustments during the integration of the two businesses, with no cancellations reported [45] Question: Recurring revenue and digital offerings - The increase in recurring revenue above 50% was primarily due to seasonality in equipment revenue recognition, with ongoing efforts to integrate digital offerings [66] Question: Cost mitigation strategies - Management discussed various strategies to mitigate tariff impacts, including reallocating demand to domestic suppliers and adjusting purchasing strategies [78][80] Question: Integration progress and potential demand changes - Management expressed confidence in managing costs and achieving synergies, but noted that lower demand could impact material purchasing and synergy savings [92]

Financial Data and Key Metrics Changes - JBT Morell's first quarter revenue exceeded guidance by $19 million, driven by better-than-expected equipment shipments and strong recurring revenue [17] - Adjusted EBITDA margin was 13.1%, outperforming guidance by 60 basis points, attributed to volume flow-through, favorable mix, and good expense control [17] - Free cash flow for the quarter was $18 million, including approximately $42 million in one-time M&A related payments [19] Business Line Data and Key Metrics Changes - JBT segment revenue increased by 4% year over year, or 5.6% on a constant currency basis, with adjusted EBITDA of $61 million, a 6% increase [18] - MRL segment revenue was flat year over year but grew 2% on a constant currency basis, with adjusted EBITDA of $51 million, a 19% increase [19] Market Data and Key Metrics Changes - Demand from the poultry industry continued to recover, contributing to a 12% year-over-year increase in orders [6] - The company experienced broad-based strength across global regions, with healthy orders in meat, beverage, pharma, and pet food [6] Company Strategy and Development Direction - The company is focused on integrating its operations to enhance service capabilities and product offerings, positioning itself as a leader in sustainable food solutions [15] - JBT Morell aims to leverage its global footprint and available capacity to manage tariff impacts and maintain competitive positioning [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic uncertainties and tariff impacts, noting that approximately half of the revenue comes from resilient recurring sources [11] - The company has temporarily suspended full-year financial guidance due to uncertainties but provided second-quarter guidance reflecting strong competitive positioning [21] Other Important Information - The estimated annualized cost impact from tariffs is approximately $50 million to $60 million, with efforts underway to mitigate these costs [10] - The company is on track to achieve targeted cost synergies of $150 million by the end of 2027 [20] Q&A Session Summary Question: Thoughts on guidance and customer behavior changes - Management indicated that the decision to pull full-year guidance was due to lack of clarity in the environment, with no significant changes in customer behavior noted [26][28] Question: Differences in customer behavior between U.S. and international markets - Management noted ongoing conversations regarding equipment pricing and potential shifts in manufacturing locations due to tariffs, but demand remains strong [30][33] Question: Impact of tariffs on recurring revenue - Management believes that recurring revenue will remain strong, with no significant pullback observed in parts orders [35] Question: Details on backlog and order delays - Management clarified that backlog figures may differ due to foreign exchange impacts and adjustments during the integration process, with no cancellations reported [45] Question: Insights on fish market performance - Management noted challenges in the white fish market but highlighted improvements in the salmon industry, indicating a positive outlook for production growth [62][65]

Financial Data and Key Metrics Changes - For Q1 2025, the company achieved revenue of $19.5 million, an 11% increase from $17.6 million in Q1 2024 [4][11] - Gross profit margin was reported at 76.1%, consistent with Q1 2024 [12] - GAAP diluted earnings per share increased by 16% to $0.37 from $0.32 in Q1 2024 [13] - Non-GAAP adjusted net income was $5.3 million or $0.42 per diluted share, up 17% from $4.6 million or $0.36 per diluted share in Q1 2024 [14] Business Line Data and Key Metrics Changes - Revenue from IV infusion pump systems grew 16% to $6 million, while disposable revenue increased 23% to $4.9 million [11][12] - Patient vital signs monitoring systems revenue remained steady at $6.5 million [12] - Domestic sales accounted for 82% of total revenue, up from 76% in Q1 2024, with domestic revenue increasing 19% to $16 million [12] Market Data and Key Metrics Changes - International sales declined 15% to $3.5 million [12] - Device revenue increased 9% to $13 million, driven by pump revenue and FMD systems [12] Company Strategy and Development Direction - The company is focused on increasing monitoring sales in 2025, anticipating a decline in pump revenues later in the year [21] - The new 3,870 MRIV pump is expected to be a revenue driver in 2026, with clearance anticipated in mid-2025 [9][10] - The company is nearing completion of a new facility, with full operations expected by July 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the impact of tariffs, noting that only 3% of revenue is connected to high tariff sources [6][7] - The FDA's responsiveness has been positive, with ongoing interactions indicating progress towards device clearance [25][27] - The company expects Q2 2025 revenue guidance of $19.7 million to $19.9 million, reiterating full-year revenue guidance of $78 million to $82 million [10] Other Important Information - Operating expenses were $9.4 million, or 48% of revenue, down from 49% in Q1 2024 [12] - Cash flow from operations was $4.3 million, up 10% from $3.9 million in Q1 2024 [14] Q&A Session Summary Question: Any anomalies in disposable revenue growth? - Management indicated that some backlog was worked down in Q1, contributing to the growth, but expects future growth to align with capital growth [17][18] Question: Confidence in monitoring sales recovery? - Management emphasized efforts to boost monitoring sales through adjusted compensation structures, with strong bookings already seen in Q2 [20][22] Question: Status of FDA interactions and clearance timeline? - Management noted ongoing interactive questions from the FDA, suggesting a positive sign, with expectations for clarity in the next three to four weeks [24][27]

Financial Data and Key Metrics Changes - The company reported revenue of $193 million and EBITDA of $20 million for the first quarter, meeting expectations [16] - Orders increased by 6% to $201 million, resulting in a book-to-bill ratio of 104% [16] - Free cash flow generated in the first quarter was $7 million, three times higher than the same period last year, marking the seventh consecutive quarter of positive free cash flow generation [22] Business Line Data and Key Metrics Changes - The Drilling and Completion segment saw a revenue increase of $5 million, driven by a rebound in sales of consumables and capital equipment [17] - The artificial lift and downhole segment experienced a decline in revenues due to unfavorable product mix and timing of shipments [18] - The Valve Solutions product line faced negative headwinds due to tariffs impacting demand, leading to a buyer strike [20] Market Data and Key Metrics Changes - Oil prices have declined significantly, hovering near four-year lows, which may lead to a reduction in rig counts and revenue starting in the third quarter if prices do not rebound [8] - The company anticipates a modest 2% to 5% decline in global drilling and completions activity for the year, with North America rig count expected to soften [13] Company Strategy and Development Direction - The company is focusing on mitigating tariff impacts, optimizing the supply chain, and reducing costs and inventory [9] - Plans include increasing assembly activities in Saudi Arabia and Canada to serve global markets more efficiently [11] - The company aims to utilize 50% of free cash flow for debt reduction and the remaining for strategic investments, including share repurchases [24] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns about economic uncertainty due to trade policies and commodity price pressures, indicating a potential decline in revenue if oil prices do not recover [7][8] - The company remains confident in its ability to generate free cash flow and maintain a strong balance sheet, with no debt maturities until 2028 [23] - Long-term growth is expected to be driven by increasing energy demand due to population growth and economic expansion [29] Other Important Information - The company has strategically de-risked its supply chain to minimize dependence on specific countries and provide sourcing flexibility [11] - The balance sheet has improved significantly, with a net debt of $146 million and a net leverage ratio of 1.56 times [23] Q&A Session Summary Question: Can you elaborate on the strength in the Subsea side despite a slowdown in rig counts? - Management highlighted strong bookings in Subsea due to customer adoption of new products and a significant market share in remote-operated vehicles [35][36] Question: What products saw strength in the drilling completion segment? - Management noted a rebound in sales of frac pump power ends and wireline products, indicating increased activity despite fewer crews [38][40] Question: How are share repurchases managed in relation to leverage ratios? - Management explained that share repurchases are timed based on net debt measurements within 30 days of buying back shares, allowing flexibility in execution [46][47] Question: What is the impact of tariffs on pricing and demand? - Management acknowledged that tariffs have led to a buyer strike in the valve product line, affecting demand and pricing strategies [54][82] Question: How does the company plan to manage cash and debt reduction? - The company plans to use half of its free cash flow for net debt reduction and will continue to monitor market conditions for share repurchases [84][85] Question: What is the outlook for the Veraperm product line in Canada? - Management indicated that the recent performance was temporary and attributed to customer and product mix, with expectations for improvement in the second half of the year [63][65]

Financial Data and Key Metrics Changes - Sales for Q1 2025 were $417 million, a decrease of 2.4% compared to $427 million in the same period last year, primarily due to unfavorable foreign exchange and lower volumes [16][26] - Adjusted EBITDA was $82 million, or 19.6%, compared to $80 million, or 18.8%, in the prior period [17][28] - Adjusted earnings per share was $0.63 in Q1 2025, up from $0.60 last year [29] - Adjusted free cash flow was $20 million, compared to an outflow of $13 million in the prior year [29] Business Line Data and Key Metrics Changes - The company reported a gross margin of $111 million for Q1 2025, slightly down from $112 million in Q1 2024 [26] - Selling, administrative, and research expenses increased to $55 million, up by $2 million from the same period last year [27] - Joint venture income was $9 million, down $1 million from the previous year [27] Market Data and Key Metrics Changes - The company expects the heavy-duty market in the U.S. to decline by 5% to 15% and medium-duty production to decrease by 10% to 20% [23][24] - The overall expected total company revenue for 2025 remains in a range of flat to up 4% compared to the prior year, with global sales expected between $1.67 billion and $1.735 billion [24] Company Strategy and Development Direction - The company is executing a four-pillar growth strategy focused on growing share in first fit, accelerating profitable growth in the aftermarket, transforming the supply chain, and expanding into the industrial filtration market [11][12][15] - The company is actively pursuing inorganic growth opportunities in industrial filtration, although economic uncertainty is softening M&A activity [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the evolving tariff environment, although the overall impact on end markets remains unclear [18][19] - The company anticipates a flat year-over-year performance in aftermarket revenue, with pricing expected to contribute approximately 3.2% to revenue growth [20][21] - The management is closely monitoring regulatory changes and their potential impacts on the business, particularly regarding emissions standards [75][76] Other Important Information - The company has repurchased $10 million of stock in Q1 2025, bringing the total repurchased since the program announcement to $30 million [6] - The effective tax rate for Q1 2025 was 21.3%, down from 22% the previous year [30] - The company ended the quarter with $183 million in cash and $583 million in available liquidity [31] Q&A Session Summary Question: Potential manufacturing transitions due to tariffs - Management indicated that they are not planning long-term manufacturing changes but are focused on short-term mitigation actions such as utilizing USMCA certifications and adjusting delivery routes [35][36] Question: M&A opportunities in the current environment - Management acknowledged that while the market has made M&A activity more challenging, they remain focused on building a strong pipeline of potential targets [39] Question: Revenue outlook amidst currency and market changes - Management confirmed that the revenue outlook remains near the midpoint of their guidance, despite market softness and changes in freight activity expectations [44][45] Question: Pricing expectations for the year - Management expects pricing to ramp up throughout the year, with a gradual increase leading to an overall expectation of 3.2% for the full year [50] Question: Impact of potential rollback of emission standards - Management is monitoring the regulatory review closely and believes they are well-positioned to support customers regardless of the outcome [76][78] Question: Shipping route reconfigurations to mitigate tariffs - Management confirmed that they have already enacted some shipping route adjustments and are continuously looking for additional mitigation strategies [85]